Prostate Cancer

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Daniel J. George, MD, discusses staples of treatment in metastatic prostate cancer as well as novel therapies and emerging strategies in the field.

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

Leonard G. Gomella, MD, discusses the growth of genetic testing in prostate cancer, how to determine who should undergo testing, and what the future holds in this space.